AIRNA Bio Raises $155M Series B To Advance RESTORE+ RNA Editing Pipeline

AIRNA Bio has raised $155,000,000. AIRNA is a biotech company focused on RNA editing therapeutics to restore the health of patients with rare and common diseases. The company is developing a pipeline of RNA editing candidates driven by its RESTORE+ platform, which it describes as powerful and flexible, and it is led by an experienced team working to advance multiple programs. The size of the raise is significant for a company at this stage because it expands available resources for research and development across a technology-driven pipeline. Allocation details were not disclosed; however, the capital should allow AIRNA to sustain and potentially accelerate work on its RESTORE+ platform and associated programs, support preclinical and development activities, and maintain organizational operations as it progresses toward key technical and regulatory milestones. The funding may also provide runway for further validation efforts needed to translate RNA editing approaches toward clinical testing. This financing comes as interest in nucleic acid and gene-modifying therapies continues to grow, and it positions AIRNA to pursue its stated objective of advancing RNA editing therapeutics. The company will need to demonstrate the safety, specificity, and durability of its candidates through rigorous studies and regulatory pathways. Over the coming months, observers will look for updates on program advancement, preclinical results, and any plans for clinical development that clarify how the company intends to deploy the new capital.